DaVita
DVA
$196.87
+1.16%
DaVita Inc. is a leading provider of kidney dialysis services, operating primarily in the United States with a significant international presence. As the largest provider of dialysis services in the U.S., holding approximately 35% market share by clinics, the company operates a network of over 3,000 facilities and treats about 280,000 patients globally each year. The current investor narrative is heavily influenced by the company's unique payer mix, where government programs like Medicare constitute about two-thirds of U.S. revenue, while commercial insurers, representing a smaller patient base, contribute nearly all domestic profits. Recent price action and financial trends suggest significant market reassessment, potentially driven by earnings results, reimbursement rate developments, or strategic updates from this healthcare services giant.…
DVA
DaVita
$196.87
Related headlines
Investment Opinion: Should I buy DVA Today?
Rating: Hold. The core thesis is that DaVita's powerful recent momentum has fully priced in near-term optimism, leaving limited margin for error given concrete fundamental pressures, making the risk/reward balanced at current levels.
Supporting Evidence: The stock trades at a reasonable forward P/E of 11.63x based on consensus EPS of $18.12, but this follows a 74% YTD surge. Revenue growth is steady at ~10% YoY, but profitability is declining, with Q4 net margin down 140 bps YoY. The company generates strong free cash flow ($1.31B TTM), supporting its operations. However, the implied upside based on forward earnings is muted given the stock is already at the top of its 52-week range.
Risks & Conditions: The two biggest risks are 1) further gross margin compression below 28%, and 2) a failure to break above the $202.69 resistance, triggering a technical reversal. This Hold rating would upgrade to a Buy if the stock pulls back meaningfully (e.g., to the $160-$170 range) while margin trends stabilize, offering a better entry point. It would downgrade to a Sell if Q1 2026 results show gross margins falling below 27% or if the stock breaks below its 50-day moving average on high volume. Relative to its own history and the healthcare services sector, the stock is fairly valued, not cheap, after its dramatic run.
Sign up to view all
DVA 12-Month Price Forecast
The outlook is clouded by the conflict between strong price momentum and deteriorating fundamentals. The base case of consolidation is most likely, as the market digests whether the margin decline is cyclical or structural. The stock's low beta suggests its fate is tied to company-specific execution on costs over the next few quarters. The stance would upgrade to bullish on evidence of sustained margin recovery (gross margin >29% for two consecutive quarters) or a significant pullback to the $160-$170 range. It would turn bearish if the stock breaks below $180 on high volume with confirming weak margin data.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on DaVita's 12-month outlook, with a consensus price target around $255.93 and implied upside of +30.0% versus the current price.
Average Target
$255.93
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$158 - $256
Analyst target range
Analyst coverage for DaVita appears limited, with only two analysts providing estimates for future EPS and revenue. The consensus estimated EPS for the coming period is $18.12, with a range from $17.72 to $18.77. Revenue is estimated to average $15.89 billion. The provided institutional ratings data shows a pattern of neutral to cautious sentiment, with recent actions including a 'Buy' from UBS and an 'Equal Weight' from Barclays in February 2026, and a 'Hold' from TD Cowen and an 'Underperform' from B of A Securities in late 2025. The wide target price range implied by the EPS estimates and the mix of analyst ratings—from Underperform to Buy—signals high uncertainty and a lack of strong consensus on the stock's future direction. A 'Buy' rating assumes successful execution and favorable reimbursement environments, while an 'Underperform' likely prices in risks from regulatory pressure, margin compression, or a high debt load. The limited number of analysts covering the stock suggests it may have less institutional following than larger-cap peers, which can contribute to higher volatility and less efficient price discovery, as seen in the stock's dramatic price moves in early 2026.
Bulls vs Bears: DVA Investment Factors
The investment debate for DaVita is sharply divided between powerful technical momentum and concerning fundamental pressures. The bull case is driven by a dominant market position, attractive valuation multiples relative to earnings, and explosive recent price action suggesting a positive catalyst. The bear case highlights severe margin compression, an overextended technical setup, and a risky financial structure. Currently, the bearish evidence holds stronger weight due to the concrete deterioration in profitability metrics (gross margin down 418 bps YoY) occurring alongside the massive price surge, creating a dangerous disconnect. The single most important tension is whether the recent price surge correctly anticipates a reversal of the margin decline and favorable reimbursement developments, or if it represents a speculative overshoot that will correct sharply when Q1 2026 results confirm ongoing cost pressures.
Bullish
- Powerful Technical Momentum: The stock is in a sustained uptrend, up 74.43% YTD and 39.09% over the past year, significantly outperforming the S&P 500. Recent momentum is exceptional, with a 38.16% gain in one month, suggesting a strong company-specific catalyst has driven the price to test its 52-week high of $202.69.
- Attractive Valuation on Earnings: Despite the sharp price appreciation, the stock trades at a trailing P/E of 13.10x and a forward P/E of 11.63x, which is below the broader market average and suggests the market is not pricing in excessive growth. The forward P/E implies an earnings growth expectation, supported by analyst consensus EPS of $18.12.
- Strong Free Cash Flow Generation: The company generates robust free cash flow, with TTM FCF of $1.31 billion. This provides significant internal funding for operations, debt management, and potential shareholder returns, underpinning financial stability despite a complex capital structure.
- Dominant Market Position: As the largest U.S. dialysis provider with ~35% market share and over 3,000 facilities, DaVita benefits from significant scale and a stable, recurring revenue base from a critical healthcare service, treating about 280,000 patients globally annually.
Bearish
- Severe Margin Compression: Profitability is under pressure, with Q4 2025 gross margin contracting to 28.28% from 32.46% a year ago, and net margin falling to 6.47% from 7.87%. This indicates significant cost inflation or an unfavorable shift in the payer mix, directly impacting earnings quality.
- Extreme Price Appreciation & Overextension: Trading at 98.5% of its 52-week high after a 100%+ range, the stock appears technically overextended. The low beta of 0.836 confirms these gains are company-specific, making the stock vulnerable to a sharp pullback on any fundamental disappointment.
- Weak Balance Sheet Structure: The company has negative shareholder equity, resulting in a debt-to-equity ratio of -23.12 and a negative ROE of -1.15%. While common for DaVita due to buybacks, this structure increases financial risk and makes traditional equity-based metrics unreliable.
- Regulatory & Payer Concentration Risk: Approximately two-thirds of U.S. revenue comes from government payers (primarily Medicare) at lower reimbursement rates. Nearly all profits come from commercial insurers representing only ~10% of patients, creating high sensitivity to policy changes and insurer negotiations.
DVA Technical Analysis
The stock is in a powerful, sustained uptrend, having gained 39.09% over the past year and 74.43% year-to-date, significantly outperforming the S&P 500's 25.19% 1-year return. With a current price of $199.74, the stock is trading at 98.5% of its 52-week high of $202.69, indicating it is testing major resistance at the top of its range, a sign of strong momentum but also potential overextension. The stock's beta of 0.836 suggests it is about 16% less volatile than the broader market, which is notable given the recent sharp price appreciation. Recent momentum has been exceptionally strong, with the stock up 38.16% over the past month and 34.10% over the past three months, significantly outpacing the S&P 500's 5.6% and 8.42% gains over the same periods. This acceleration from the longer-term trend suggests a powerful, recent catalyst has driven the stock higher, as evidenced by the dramatic price surge from around $111 in early February to nearly $200 by mid-May. The stock's 1-month relative strength of 32.56 points underscores this exceptional outperformance. Key technical levels are clear: immediate resistance is at the 52-week high of $202.69, with a breakout above potentially signaling a continuation of the bullish momentum. Support lies much lower, around the 52-week low of $101.00. The stock's low beta of 0.836 suggests its recent explosive gains are not driven by market-wide risk-on sentiment but by company-specific factors, making the current high valuation levels particularly sensitive to any fundamental disappointments. The 52-week range of over 100% highlights the stock's significant volatility within its own context.
Beta
0.84
0.84x market volatility
Max Drawdown
-31.4%
Largest decline past year
52-Week Range
$101-$203
Price range past year
Annual Return
+35.1%
Cumulative gain past year
| Period | DVA Return | S&P 500 |
|---|---|---|
| 1m | +31.8% | +4.6% |
| 3m | +33.6% | +8.3% |
| 6m | +63.7% | +12.5% |
| 1y | +35.1% | +25.0% |
| ytd | +71.9% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DVA Fundamental Analysis
DaVita's revenue trajectory shows steady growth, with Q4 2025 revenue of $3.62 billion representing a 9.87% year-over-year increase from the prior-year quarter. The quarterly trend through 2025 reveals consistent top-line expansion, with revenue growing sequentially from $3.22 billion in Q1 to $3.62 billion in Q4. The company's core U.S. Dialysis and Related Lab Services segment generated $10.12 billion over the reported period, driving this growth. This consistent revenue growth, in a mature industry, suggests stable patient volumes and effective pricing management, though the growth rate is moderate. The company is profitable, reporting Q4 2025 net income of $234.2 million and an EPS of $2.51. However, profitability metrics show some compression; the Q4 net margin was 6.47%, down from 7.87% in Q4 2024. The gross margin for Q4 2025 was 28.28%, also down from 32.46% in the year-ago quarter, indicating potential cost pressures or reimbursement mix shifts. The operating margin for the quarter was 15.23%, which remains healthy for the healthcare services sector, but the year-over-year decline in net and gross margins warrants monitoring for margin sustainability. DaVita maintains a solid balance sheet with a current ratio of 1.29, indicating sufficient short-term liquidity. The company generates robust free cash flow, with TTM free cash flow of $1.31 billion, providing ample internal funding for operations and shareholder returns. However, the debt-to-equity ratio is a notable -23.12, which is an accounting artifact stemming from negative shareholder equity, a common feature for DaVita due to its capital structure and history of significant share buybacks. The Return on Equity (ROE) is also negative at -1.15, further reflecting the negative equity base, while Return on Assets (ROA) is a positive 7.50%, showing efficient use of assets to generate earnings.
Quarterly Revenue
$3.6B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.28%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DVA Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. DaVita trades at a trailing P/E of 13.10x and a forward P/E of 11.63x based on analyst estimates. The lower forward multiple suggests the market anticipates earnings growth, with the forward P/E implying an earnings growth expectation embedded in the current price. Compared to industry averages, DaVita's valuation appears mixed. Its trailing P/E of 13.10x is below the typical market average for profitable companies, which often trade above 20x, but this must be contextualized within the healthcare services sector, which often trades at lower multiples due to regulatory and reimbursement risks. The stock's Price-to-Sales (P/S) ratio of 0.72x and EV/Sales of 1.93x suggest the market is valuing its revenue stream at a moderate multiple, potentially reflecting its stable, government-reimbursed cash flows. Historically, DaVita's valuation has fluctuated significantly. The current trailing P/E of 13.10x sits well below its own historical highs seen in recent years, where the P/E ratio reached above 15-18x in 2024 and early 2025. This suggests the stock, despite its recent price surge, is not at peak historical valuation multiples on an earnings basis. However, the negative Price-to-Book (P/B) ratio of -15.02 is not a meaningful comparison due to the negative shareholder equity, a persistent feature of its capital structure.
PE
13.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~25x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on profitability sustainability and capital structure fragility. The year-over-year contraction in gross margin (from 32.46% to 28.28%) and net margin (from 7.87% to 6.47%) signals rising costs or unfavorable reimbursement mix that could compress earnings further. The negative shareholder equity, resulting in a debt-to-equity ratio of -23.12, is a persistent accounting artifact but limits financial flexibility and makes the company more vulnerable to rising interest rates. Revenue concentration is also a risk, with nearly all U.S. profits dependent on commercial insurers covering only ~10% of patients.
Market & Competitive Risks are elevated by the stock's extreme re-rating. Trading at a forward P/E of 11.63x, while not excessive historically, follows a 74% YTD surge, creating high valuation compression risk if growth expectations are not met. The low beta of 0.836 indicates the rally is idiosyncratic, not market-driven, increasing its fragility. Competitive and regulatory risks are perennial; any reduction in Medicare reimbursement rates or loss of commercial insurer contracts would directly impair the profitable core of the business. The lack of analyst consensus (ratings from Underperform to Buy) reflects this uncertainty and can lead to heightened volatility.
Worst-Case Scenario involves a 'double miss' of earnings and guidance, confirming margin pressures are structural, not transient. This could trigger multiple compression as the growth narrative unwinds, combined with analyst downgrades. A realistic downside target is a return to the 52-week low of $101.00, which would represent a loss of approximately -49% from the current price of $199.74. This scenario could be catalyzed by a disappointing Q2 2026 earnings report showing continued gross margin erosion below 28%.
FAQ
The key risks are, in order of severity: 1) Profit Margin Erosion: Gross margin fell 418 bps YoY to 28.28% in Q4; continued decline would crush earnings. 2) Valuation & Technical Risk: The stock is up 74% YTD and trades at 98.5% of its high, making it vulnerable to a sharp correction. 3) Regulatory/Payer Risk: Nearly all profits depend on commercial insurers (~10% of patients); policy or pricing changes could be devastating. 4) Financial Structure Risk: Negative shareholder equity (Debt/Equity: -23.12) is an accounting quirk but indicates a leveraged, non-traditional balance sheet.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock consolidating between $180 and $210, as steady revenue growth battles margin pressures, aligning with the analyst EPS consensus of $18.12. The Bull Case (25% probability) targets $220-$240, requiring margin stabilization and a successful breakout above $202.69. The Bear Case (20% probability) warns of a drop to $101-$150 if margin compression accelerates, triggering a momentum reversal. The most likely outcome is the Base Case, hinging on the assumption that cost pressures do not worsen significantly.
DVA appears fairly valued relative to its earnings. The forward P/E of 11.63x is below the broader market average and not at a historical peak for the company, suggesting it is not egregiously overvalued. However, the Price-to-Sales ratio of 0.72x and EV/Sales of 1.93x reflect the market's moderate valuation of its revenue streams, considering the regulatory risks. The valuation implies the market expects moderate earnings growth but is also discounting the stock for its margin pressures and complex balance sheet. It is not cheap enough to be called undervalued after its massive run.
DVA is a Hold, not a clear Buy, at the current price of $199.74. The recent 74% YTD surge has likely priced in near-term optimism, leaving limited upside to the analyst-implied base case without a significant improvement in fundamentals. The stock offers a reasonable forward P/E of 11.63x, but this is counterbalanced by clear margin compression and an overextended technical chart. It could be a good buy for a patient, valuation-sensitive investor only on a significant pullback (e.g., towards $170), which would improve the risk/reward profile substantially.
DVA is more suitable for a medium-term, tactical investment horizon (6-18 months) rather than a long-term buy-and-hold or short-term trade. Its low beta (0.836) and lack of a dividend make it a poor fit for income investors or those seeking stable, long-term compounding. The current investment thesis revolves around the resolution of near-term margin trends and technical patterns, which will likely play out over the next few quarters. Investors should be prepared for high volatility, as evidenced by its 100%+ 52-week range, and consider taking profits or cutting losses based on upcoming earnings results.
